Can GLP-1 Medications Help With Alcohol Use Disorder? What the Evidence Shows

Direct Answer

Real, published clinical evidence suggests semaglutide may help reduce drinking and alcohol cravings in people with alcohol use disorder, but this is not yet an FDA-approved use, and it remains under active clinical investigation, not an established treatment you can simply request for this purpose.

The Real Evidence So Far

A randomized, placebo-controlled trial published in The Lancet on May 2, 2026 (108 participants, led by Copenhagen University Hospital) found that semaglutide combined with cognitive behavioral therapy significantly reduced heavy drinking days compared to therapy alone. A separate, earlier phase 2 trial published in JAMA Psychiatry (48 participants) found low-dose semaglutide reduced both alcohol consumption and craving, with real, statistically significant effect sizes. A large observational study published in the BMJ also found people prescribed GLP-1 medications had lower rates of alcohol and substance use disorders compared to those on other diabetes medications.

Why This Is Real, Current News

The U.S. Department of Veterans Affairs launched a nationwide clinical trial specifically studying semaglutide for alcohol use disorder in veterans, with recruitment opening July 28, 2026. More than 400,000 veterans currently carry an AUD diagnosis. This is a real, active, government-run study, not yet a treatment recommendation.

An Important Caution, Directly From the VA

The VA has explicitly and directly cautioned: "VA strongly discourages self-medicating or attempting to replace other AUD treatment options with GLP-1 medications or any other unprescribed substances." Evidence-based, FDA-approved treatments for alcohol use disorder already exist and remain the appropriate first path, this research is genuinely promising, but it is not yet a substitute for established care.

Bottom Line

This is real, legitimate, actively growing research, not a settled treatment. If you're struggling with alcohol use, the responsible next step is a conversation with your healthcare provider about proven, currently available treatment options, not self-directed use of a GLP-1 medication for this purpose.

Related Resources

• Are GLP-1 Medications FDA-Approved for Alcohol Use Disorder?
• GLP-1 and Alcohol Use Disorder: Current Clinical Trials

If You Need Support

If you or someone you know is struggling with alcohol use, the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline is available 24/7 at 1-800-662-4357, free and confidential.

References

• The Lancet: Once-Weekly Semaglutide vs. Placebo in Alcohol Use Disorder and Comorbid Obesity (May 2, 2026)
• JAMA Psychiatry: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
• U.S. Department of Veterans Affairs: VA Launches Trial of GLP-1 Treatment for Alcohol Use Disorder (July 2026)
• NIH: GLP-1 Plus Therapy Can Reduce Heavy Drinking

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice. If you are experiencing a mental health or substance use crisis, please seek immediate professional support.